MYB-AS1: MYB-AS1 is an antisense long non-coding RNA (lncRNA) that is expressed predominantly in pre-B1 and pre-B2 cells and originates from a protein-coding gene involved in B cell development [PMC7072530]. It has been reported to be expressed in various stages of B-cell development [PMC7072530]. MYB-AS1 has been implicated in the pathogenesis of acute myeloid leukemia (AML) [PMC7388210]. A 14-lncRNA risk score system, which includes MYB-AS1, has been proposed for the prediction of AML prognosis [PMC7388210]. MYB-AS1 is one of the antisense lncRNAs associated with early B cell development and is linked to the expression of MYB, a known early B cell transcription factor [PMC8698845] [PMC5890390]. In a prognostic risk model for tumor tissues, MYB-AS1 was found to be downregulated, suggesting its potential protective role in cancer progression [PMC9004096]. MYB-AS1 is a simple transcript with two exons and its expression has been associated with early B-cell development-specific genes such as RAG2, VPREB1, DNTT, LEF1, SMAD1, and MYB [PMC8430640] [PMC8305593] [PMC5601166]. It has also been identified as one of the hub lncRNAs involved in various biological processes including cancer development and progression [PMC6710062]. In combination with PAX8 antisense RNA 1 (PAX8-AS1), MYB-AS1 can serve as an effective predictor for AML prognosis in children [PMC9560823].